XLO FY 2024 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

XLOXilio Therapeutics, Inc.

$28M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M

Gross Profit

$6M100.0% margin

Operating Income

-$61M-954.9% margin

Net Income

-$58M-918.0% margin

EPS (Diluted)

$-1.09

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$71M

Total Liabilities

$53M

Stockholders' Equity

$18M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$0	—
Gross Profit	$6M	$0	—
Operating Income	-$61M	-$79M	+23.4%
Net Income	-$58M	-$76M	+23.8%